modelTranexamicAcid
Extends from Pharmacolibrary.Drugs.ATC.B.B02AA02.
Information
| name: | TranexamicAcid | |
| ATC code: | B02AA02 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 9 | L |
| clearance: | 110 | mL/min |
| other parameters in model implementation | ||
Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, thereby preventing fibrinolysis and stabilizing blood clots. It is primarily used to treat or prevent excessive bleeding in various medical conditions, including during surgery, trauma, heavy menstrual bleeding (menorrhagia), and in certain bleeding disorders. Tranexamic acid is approved for use in many countries worldwide.
Pharmacokinetics
Single-dose intravenous administration in healthy adult volunteers.
References
González Osuna, A, et al., & Valle, M (2022). Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. Clinical pharmacokinetics 61(1) 83–95. DOI:10.1007/s40262-021-01043-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34255299
Li, S, et al., & Gobburu, JVS (2021). Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. British journal of clinical pharmacology 87(9) 3531–3541. DOI:10.1111/bcp.14767 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33576009
Grassin-Delyle, S, et al., & Shakur-Still, H (2022). Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. British journal of anaesthesia 128(3) 465–472. DOI:10.1016/j.bja.2021.10.054 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34998508
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)